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Data on the impact of biological therapies on the T-cell phenotype in rheumatoid arthritis are limited. Here, we
prospectively measured the percentages of 15 circulating T-cell subtypes using flow cytometry. We obtained transversal
and longitudinal data in 30 anti-TNF responders, 19 secondary anti-TNF nonresponders, and 43 IL-6R antagonist
responders, before, 8 weeks and at least 6 months after biological therapy. Untreated RA patients and healthy controls
were also included. The important findings are the following: (1) the proportion of regulatory T-cells (Tregs) which are
decreased in untreated RA patients becomes normal in all long-term-treated groups; (2) in anti-TNF responders as well
as in nonresponders, the frequencies of naïve CD4+ and CD8+ cells are lower, whereas those of proinflammatory Th1,
Th2, and Th17 cells and HLA-DR+-activated cells are higher than those in untreated RA or healthy controls; (3) in IL-6R
responders, Th1 proportion is decreased, while that of Th2 and Th17 is increased as compared to that in anti-TNF-treated
patients and controls; (4) pending confirmation, a CD4CD69 ratio< 2.43 at baseline, could be useful to predict a good
therapeutic response to anti-TNF therapy. This study provides comprehensive information regarding the long-term
impacts of those biological therapies on the ecotaxis of T-cells in RA. The ClinicalTrials.gov registration number of our
study is NCT03266822.
1. Introduction
Rheumatoid arthritis (RA) is the most common chronic
autoimmune joint disease, which leads to progressive articu-
lar destruction without treatment [1]. The abnormal function
of CD4+ and CD8+ cells plays a key role in the autoimmune
process leading to the development of RA. This is reflected by
a number of observations indicating that the proportion of
different CD4+ subsets responsible for the harmonized
immune response is skewed to a proinflammatory direction.
The frequency of Th1, Th2 helper, and proinflammatory
Th17 cells is increased [2, 3], while that of regulatory
T-cells (Treg) is decreased in the peripheral blood of RA
patients [4–7]. Biological therapies, including monoclonal
antibodies targeting tumor necrosis factor-α (TNF) and
interleukin-6 receptor (IL-6R), have emerged as disease-
modifying agents with much higher therapeutic potential
than conventional immunosuppressive therapies. Little is
known about how the alterations in the T-cell subset compo-
sition are affected by anti-TNF or anti-IL-6R drugs. Few
studies, including our previous examinations [7], followed
T-cell subset prevalence changes, but in most of them, only
short-term follow-up was evaluated [8–15]. As changes in
cell numbers are supposed to require longer time, we
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presume that short-term follow-up may not be sufficient.
Furthermore, the number of patients was not high enough
to capture subtle changes in cell proportions; moreover,
some studies were not homogenized for disease activity
or response to therapy, or only few types of cells were
monitored. Data on the effects of IL-6R blocker therapy
are especially limited [16–18].
Our knowledge about the long-term consequences of
biological therapies is still insufficient. Data on the risk of
the susceptibility to infections, efficacy of vaccination, or
tumor development after several years of anti-TNF therapy
are not yet conclusive [19, 20]. A detailed insight into how
a sustained interference to the adaptive immune system with
biological therapies skews the status of the adaptive immune
system would provide useful information in this regard.
Furthermore, as only about 40% of patients respond with
complete remission to anti-TNF or anti-IL-6R treatment,
and the number of available therapies with different target
specificities is increasing, there is a highly recognized need
for predictors of a good response for every therapeutic agent
to establish the choice of therapy in a personalized manner.
Although some soluble predictive biomarkers have been pro-
posed [21, 22], predictors relating to the cellular component
of the immune system, as identified through a long-term
follow-up assessment, are lacking.
We aimed to answer the following questions: (1) Is the
T-cell subset distribution different in RA patients on long-
term (more than six-month duration) biological therapy as
compared to the short-term data (baseline, i.e., biological
therapy naive patients and short term: eight-week anti-TNF
therapy)? (2) Is the immune phenotype different between
anti-TNF responder and nonresponder patients? and (3)
Are there any T-cell subtypes that can be used as predic-
tors of the response to anti-TNF therapy? Finally, we
wished to analyze the T-cell phenotype in patients on
IL-6R blocker therapy.
Herein, we present a detailed description of the T-cell
phenotype of RA patients on established biological therapies,
obtained with two approaches: (1) a cross-sectional analysis
of a high number of RA patients on a long-term treatment
with anti-TNF or anti-IL-6R therapies; (2) we present the
long-term follow-up results of our prospective study of
anti-TNF-treated RA patients, in whom these parameters
have serially been measured from the start of the anti-TNF
treatment (short-term follow-up data have been published
in [7]). The evaluation of the long-term outcome of anti-
TNF therapy enabled us to evaluate which T-cell subset
changes may be predictive of a long-standing therapeutic
response to these treatment agents.
2. Patients and Methods
2.1. Patients. In the cross-sectional analysis, 92 RA patients
(who had been treated with biological therapy for more than
six months) were evaluated. All of them are treated at the
Department of Rheumatology and Immunology, University
of Szeged. Rheumatoid arthritis was classified according to
the 2010 ACR/EULAR classification criteria for RA [23].
49 patients were treated with anti-TNF therapy (adalimumab
n = 14, certolizumab pegol n = 14, etanercept n = 11, inflixi-
mab n = 6, and golimumab n = 4 patients) and 43 patients
with the anti-IL-6R agent tocilizumab. Within the anti-
TNF-treated RA patients, we distinguished anti-TNF
responder or anti-TNF nonresponder patients. For the defi-
nition of the therapeutic response, we used the EULAR good
response criteria [24]; therefore, in the responder group,
patients had a DAS28 score of ≤3.2, and its improvement
since the initiation of the biological therapy was >1.2. Since
there were insufficiently low numbers of IL-6R antagonist
nonresponder patients within our patient population, we
included only IL-6R blocker responders in this study.
We compared their results with newly diagnosed,
untreated RA patients (n = 19). Treatment-naïve, early RA
patients had not received any anti-RA treatment prior to
our study. The measurements on this cohort of patient have
been published earlier [7]. The detailed clinical data and
patient characteristics are presented in Table 1. ACPA was
measured using ELISA-based routine laboratory methods
with specificity to mutated citrullinated vimentin.
As a further control group (healthy controls), we enrolled
30 age- and gender-matched healthy volunteers (18 men,
12 women; mean age 52.4 years range (24–63.5). All of them
had a negative history of RA symptoms and a negative status
upon detailed physical and laboratory examination including
normal CRP and ESR values.
The prospective follow-up cohort included 13 of the anti-
TNF-treated patients, in whom T-cell frequency values at the
initiation of anti-TNF therapy and 8 weeks thereafter were
measured earlier [7]. Six of them have become (secondary)
nonresponders in the long-run (i.e., since the completion of
the short-term follow-up), whereas 7 of them remained to
be long-term responders to anti-TNF therapy. Average age
of these 13 patients was 59 (39–65) years, and the mean
duration of anti-TNF treatment was 27 (11–52) months;
there was no statistically significant difference between the
two groups in either of these parameters. The conditions of
the present laboratory measurements and all the clinical
assessments were fully identical to those described for the
study on therapy-naïve patients and those on short-term
anti-TNF therapy [7].
Informed consent was signed by all participants, and the
protocol had been approved by the Ethics Committee of the
Ministry of Health of Hungary and Ethics Committee of
the University of Szeged (ETT-TUKEB905/PI/09).
2.2. Flow Cytometry Measurements. Blood samples were
taken in the laboratory unit of the Department of Rheuma-
tology and Immunology. We used 15ml of anticoagulated
blood and separated the peripheral blood mononuclear cells
(PBMCs) by centrifugation with Ficoll-Paque (GE Health-
care Life Sciences, Pittsburgh, PA, USA). PBMCs were frozen
and kept at −80°C until analysis. After thawing, samples were
washed twice with phosphate-buffered saline solution
(pH7.4). We used fluorescent antibodies (Becton Dickinson,
San Diego, CA, USA) for cell surface staining according to
the manufacturer’s manual.
Cell subtypes were defined as helper T-cells (CD4+), Th1
cells (CD4+CXCR3+), Th2 cells (CD4+CCR4+CCR6−),
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Table 1: Clinical data and patient characteristics.
Anti-TNF
responders (n = 30)
Anti-TNF
nonresponders (n = 19)
Anti-IL-6R
responders (n = 43)
Newly diagnosed
untreated RA (n = 19)
Mean age (range) 57.2 (26–75) 55.7 (29–71) 57.5 (34–76) 48.3 (22–67)#
Gender (female/male) 19/11 12/7 28/15 11/8
Anti-TNF treatments 30 (100.0) 19 (100.0)
n (%) adalimumab 10 (33.3) 4 (21.1)
Certolizumab 6 (20.0) 8 (42.1)
Etanercept 7 (23.3) 4 (21.1)
Infliximab 4 (13.3) 2 (10.5)
Golimumab 3 (10.0) 1 (5.3)
Mean disease duration (range) 11.3 (2–33) yrs 10.8 (4–44) yrs 12.0 (2–34) yrs 2.7 (1–3) months
Adalimumab 11.9 (3–24) 11.8 (5–19)
Certolizumab 10.7 (2–31) 10.2 (4–44)
Etanercept 12.4 (2–33) 11.0 (5–26)
Infliximab 13.5 (4–22) 12.0 (5–19)
Golimumab 8.0 (3–16) 9.0
Mean duration of current biological
therapy months (range)
29.8 (6–52) 30.95 (6–50) 33.0 (6–48) —
Adalimumab 35.1 (6–52) 30.8 (24–48)
Certolizumab 28.2 (8–42) 29 (6–43)
Etanercept 26.7 (7–41) 36.8 (18–50)
Infliximab 27.6 (10–33) 22.5 (8–37)
Golimumab 31.4 (11–42) 41
Prior use of TNF inhibitors 3/30 6/19 29/43 —
No. of switching,
n: 1 3/3 4/6 15/26
2 — 2/6 9/26
3 — — 5/26
Patients on corticosteroid therapy n (%) 8 (26.7) 8 (42.1) 15 (40.5) —
Adalimumab 3/10 1/4
Certolizumab 1/6 3/8
Etanercept 2/7 2/4
Infliximab 2/4 1/2
Golimumab 0/3 1/1
Patients on conventional DMARD
therapy n (%)
26 (86.7) 15 (79.0) 23 (62.2)∗ —
Adalimumab 8/10 3/4
Certolizumab 5/6 6/8
Etanercept 6/7 3/4
Infliximab 4/4 2/2
Golimumab 3/3 1/1
ACPA positivity n (%) 24 (85.4) 14 (82.4) 21 (41.4)∗ 19 (100.0)
Adalimumab 8/10 3/4
Certolizumab 5/6 6/8
Etanercept 5/7 2/4
Infliximab 3/4 2/2
Golimumab 3/3 1/1
3Mediators of Inflammation
Th17 cells (CD4+CCR4+CCR6+), Tregs (CD4+CD25
high), naive T-cells (CD4+CD45RA+), or memory T-cells
(CD4+CD45RO+). The proportion of cells expressing early
(CD69), intermediate (CD25), or late (HLA-DR) activation
markers was also determined within both the CD4+ and
CD8+ subsets. An average of 200,000 cells were registered
for each acquisition. All measurements were performed on
a BD FACSAria flow cytometer (Becton Dickinson, San
Jose, CA, USA). Cell proportion values were determined
with conventional gating, through the use of FACSDiva
software (Becton Dickinson, San Jose, CA, USA). Figure 1
represents the gating strategy of T-helper subsets.
2.3. Statistical Methods. Data are presented as mean± SD or
median (25–75 percentile) depending on the distribution of
the values. Cell subset percentage values were compared
among groups with analysis of variance or with Kruskal-
Wallis test, with Bonferroni’s or Dunn’s tests for multiple
comparisons, respectively. Predictive value of baseline per-
centage values to subsequent response to anti-TNF therapy
was assessed with ROC analysis. A p value < 0.05 was taken
as statistically significant.
3. Results
3.1. Patient Characteristics. Thirty of the 49 anti-TNF RA
patients were responders and 19 were nonresponders, while
all of the 43 IL-6R-treated RA patients were responders. As
it can be seen in Table 1, mean ages, disease duration, and
the proportion of patients who were on low-dose corticoste-
roid therapy in these three groups were not different. Fewer
IL-6R responders took traditional DMARDs than the
anti-TNF-treated patients, and the proportion of anti-
citrullinated peptide antibody- (ACPA-) positive patients
was also lower in the IL-6R blocker-treated group. The newly
diagnosed untreated RA patients were slightly younger than
the long-term-treated patients; all of them were ACPA-
positive, and they had the highest mean DAS28 score.
3.2. Immunophenotype of Patients with RA on Long-Standing
Anti-TNF Therapy. The proportions and ratios of various T-
cell subsets are demonstrated in Table 2 and Figures 2 and 3.
3.3. Anti-TNF Responders. As compared with early, active,
untreated RA, anti-TNF responders had lower proportions
of CD4+ cells, naïve CD4+ and CD8+ cells and memory
CD8+ cells, and higher percentages of activated CD4+ T-
cells with HLADR marker positivity, but lower prevalences
of CD4+ cells with CD25 and of CD8+ T-cells with CD69
marker positivity. Anti-TNF responders were characterized
by higher Th1 and Treg frequencies than early active,
untreated RA patients.
When compared with healthy controls, anti-TNF
responders had lower proportions of CD4+ and CD8+
T-cells. The frequencies of naive T-cells (both CD4+ and
CD8+CD45RA+ cells) were lower compared with controls,
whereas those of the memory subtype (CD45RO+) were
similar among CD4+ cells and were also lower among CD8+
cells in the anti-TNF responders than in healthy volunteers.
The proportion of activated T-cells bearing the CD25
marker was lower and that of the HLA-DR+ cells (both
CD4+ and CD8+) was higher in anti-TNF responders than
in controls (Figure 2). In anti-TNF responders, Th1, Th2,
and Th17 proportion values were all higher than those in
healthy controls, but, importantly, Treg frequencies were
not different (Figure 3).
3.4. Anti-TNF Nonresponders. There are somewhat less
differences between the T-cell composition of anti-TNF non-
responders and early untreated RA patients, but naïve T-cells
(both CD4+ and CD8+) and also CD8+ memory cells are
less prevalent in anti-TNF nonresponders, similarly to
CD8CD69+-activated cells. A comparison with healthy con-
trols also revealed that anti-TNF nonresponders had lower
proportions of CD4+ and CD8+ naïve and CD8+ memory
T-cells; furthermore, CD4+CD25+-activated T-cells also
occurred less frequently in the anti-TNF nonresponders than
in the healthy subjects. The percentage of CD8+ cells was
lower in anti-TNF nonresponders than in controls, but, in
contrast with anti-TNF responders, CD4+ cell prevalence
was not different from controls (Figure 2). Similarly to the
anti-TNF responders, Th17 and Th2 percentages were also
higher in nonresponders than in the controls, and, again, Treg
frequencies were equal to the healthy controls (Figure 3).
The differences between anti-TNF responders and non-
responders, as revealed in this analysis, were significantly
lower percentages of total CD4+ and higher proportion of
CD4+HLA-DR+ T-cells in anti-TNF responders as com-
pared with anti-TNF nonresponders.
Table 1: Continued.
Anti-TNF
responders (n = 30)
Anti-TNF
nonresponders (n = 19)
Anti-IL-6R
responders (n = 43)
Newly diagnosed
untreated RA (n = 19)
DAS 28 score (mean± SD) 2.2± 0.8 5.12± 1.29+ 1.89± 0.87 7.71± 4.06#
Adalimumab 2.16± 0.79 4.64± 1.35
Certolizumab 2.09± 1.18 5.53± 0.82
Etanercept 1.70± 0.48 5.18± 1.98
Infliximab 3.00± 0.92 4.95± 0.27
Golimumab 2.36± 0.47 4.21± 0.00
∗p < 0 05 between anti-TNF responders and IL-6R blocker responders. +p < 0 05 between anti-TNF nonresponders and IL-6R blocker responders, #p < 0 05
between newly diagnosed untreated RA group and all other groups. DMARD: disease-modifying antirheumatic drug; ACPA: anti-citrullinated protein
antibody; DAS28: disease activity score with 28 joints; TNF: tumor necrosis factor alpha; IL-6R: interleukin-6 receptor.
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3.5. Immunophenotype of Patients with RA on Long-Standing
IL-6 Receptor Blocker Therapy. Most important differences
between the T-cell composition of RA patients on effective
IL-6R blocker therapy and early, active, untreated RA patients
are the strikingly low number of CD8+ cells and the higher
prevalence of Th17 and Treg cells in the IL-6R blocker-
treated patients. Naive T-cell (both CD4+ and CD8+) and
CD8+ memory cell proportions were lower in anti-IL-6R-
treated RA patients (Figures 2 and 3). As compared with
healthy subjects, some further differences can also be
observed: higher prevalence of Th2 cells and of CD4+HLA-
DR+- and CD8+CD69+-activated T-cells than in controls.
Comparisons between anti-IL-6R responders and anti-
TNF responders reveal significantly higher CD4+ and lower
CD8+ T-cell frequencies with anti-IL-6R therapy (Figure 2).
Anti-IL-6R responders had the lowest proportion of Th1 cells
in all the examined groups, and this difference was significant
from both anti-TNF responders and anti-TNF nonre-
sponders (Figure 3). On the contrary, the proportions of
Th2 and Th17 cells were higher among anti-IL-6R responders
than in anti-TNF-treated RA patients including anti-TNF
responders and anti-TNF nonresponders. Nevertheless,
similarly to anti-TNF-treated groups, Treg frequencies were
normal (Figure 3). With regards to the activated T-cell
subsets, anti-IL-6R therapy was associated with higher per-
centages of CD69+ T-cells, within both the CD4+ and the
CD8+ subsets, than anti-TNF therapy, and CD4+CD25+ cells
were also more prevalent in anti-TNF responders (Figure 2).
3.6. Time-Course of the Changes in the T-Cell Subset
Distribution in RA Patients on Long-Standing Anti-TNF
Therapy. We compared the T-cell subset proportion values
from the beginning of the disease in 13 patients (7 anti-
TNF responders and 6 anti-TNF nonresponders). As
compared with the baseline values (at disease onset, before
anti-TNF therapy initiation), percentages of total CD4+
T-cells, CD4+ and CD8+ naive T-cells decreased (Figure 4),
but those of Tregs increased over time in both anti-TNF
responders and anti-TNF nonresponders (Figure 5). Th1
and Th17 proportions increased only in the anti-TNF
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Figure 1: Gating strategy for the identification of T-helper cell subsets with flow cytometry. FSC: forward scatter characteristics; SSC: side
scatter characteristics.
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responder group, and Th2 cell frequencies increased only
within the anti-TNF nonresponders (Figure 5). CD4+
CD69+ cell proportion decreased in the anti-TNF nonre-
sponders (p < 0 05 with ANOVA, but no significant differ-
ences with Bonferroni’s correction), and CD4+HLA-DR+
cell percentages increased only in the anti-TNF responders
(Figure 5). Among CD8+ cells, memory T-cells became less
prevalent during the course of the disease only in the
anti-TNF nonresponders, while HLA-DR+-activated cell fre-
quency was gradually rising in the anti-TNF responder group
only. As it can be seen in Figures 4 and 5, most of these
changes have become evident only after long-term follow-up.
3.7. The Impact of the Length of the Biological Therapy on
T-Cell Subsets in Long-Term-Treated RA Patients. Since the
duration of biological therapies was highly variable among
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Figure 2: Proportions of various T-cell subsets in rheumatoid arthritis patient groups of anti-TNF responders (n = 30), anti-TNF
nonresponders (n = 19), and IL-6R blocker responders (n = 43), early, active, therapy-naïve RA patients (n = 19), and healthy controls
(n = 30). Data are presented as median (horizontal line within boxes), 25 and 75 percentile (horizontal borders of the boxes), and
minimum and maximum (whiskers). Ap < 0 05 versus anti-TNF responder, Bp < 0 05 versus anti-TNF nonresponder, Cp < 0 05 versus
IL-6R blocker responder, Dp < 0 05 versus early, untreated RA patients.
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long-term-treated RA patients (ranging from 6 to 52
months), the question may arise whether this wide time span
could have an impact on the long-term effects of biologicals
on the T-cell composition. We therefore further stratified the
patients according to the duration of long-term biological
therapy to “short” (6–12months), “medium” (12–18months),
and “long” (>18 months) duration of treatment. Comparison
among these subgroups has revealed that only two of the
examined 15 T-cell subtypes displayed a significant variabil-
ity across these three subgroups: the prevalences of CD4+
CD45RA+ and CD8+CD45RA+ naive cells decrease gradu-
ally among the three subgroups with longer treatment
duration and reach a significance of p < 0 05 in the compar-
ison between long-term duration versus the other two
subgroups. All the other parameters have remained stable
irrespective of the length of biological therapy (Table 3).
3.8. The Impact of Previous Switching of Anti-TNF Agents on
T-Cell Subsets. As it can be seen in Table 1, in some patients
(especially in the IL-6R blocker-treated group), the biological
agent applied at the time of sampling was not the first one,
but there were previous switches from other anti-TNF drugs.
Although these switches occurred more than 6 months
before the blood sampling, we wanted to know whether the
previous changes in therapy may have influenced the T-cell
phenotype. We therefore compared the patient subgroups
as defined by the number of previous switches in all thera-
peutic groups (Table 4). This analysis revealed that the
proportions of CD4+CD69+ and of CD8+CD69+ cells were
higher in IL-6R responder patients who had experienced
three switches before the current therapy than in those who
had only one switch before (Figure 6). Opposite difference
was observed with regard to Th1 percentage.
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3.9. Differences among the Various Anti-TNF Agents. When
we compared the T-cell subset proportions among the 5
anti-TNF agents individually (including adalimumab, eta-
nercept, certolizumab, golimumab, and infliximab) and
between the particular anti-TNF drugs and anti-Il-6R
responders or healthy controls, only one significant differ-
ence was revealed in addition to the comparisons when
the anti-TNF drugs were considered as one single group:
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Figure 4: Changes in the proportions of T-cell subsets in RA patients in whom long-term follow-up data from the initiation of anti-TNF
therapy were available (n = 13). 7 patients from the initial short-term cohort (7) proved to be long-term responders, whereas the other 6
patients lost the initial response and therefore belonged to the nonresponder group. Measurement time points: baseline: at anti-TNF
initiation, short term: 8 weeks of anti-TNF treatment (previously published data (7)), long-term: current measurement results after long-
standing anti-TNF treatment. Data are presented as median (horizontal line within boxes), 25 and 75 percentile (horizontal borders of the
boxes), and minimum and maximum (whiskers). Ap < 0 05 versus baseline, Bp < 0 05 versus short term.
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the frequencies of CD4+CD45RO+ cells were higher
among etanercept-treated patients (responders and nonre-
sponders taken together) than among IL-6R blocker
responders. The effect of the various anti-TNF agents on
the immunophenotype of the RA patients was not differ-
ent (Table 5).
3.10. Relationship between Baseline T-Cell Subset Prevalences
and Response to Therapy. Through the analysis of the pro-
spective follow-up cohort, in which we compared the T-cell
subset frequencies at baseline (i.e., at the start of the anti-
TNF therapy), short-term (8 weeks), and long-term
therapies, we examined whether any baseline parameters
are predictive of the long-term response to anti-TNF therapy.
TheproportionofCD4+CD69+T-cells atbaseline (2.16± 0.12
versus 2.69± 0.16, p = 0 08) and at 8 weeks (2.01± 0.20
versus 2.81± 0.28, p = 0 03) was lower in those who later
belonged to anti-TNF responders than in those who
became anti-TNF nonresponders. ROC analysis revealed
that a CD4+CD69+ T-cell percentage< 2.43 at baseline
predicts a future response to anti-TNF therapy with a like-
lihood ratio of 4.29 (CI: 0.58–1.06) and discriminates
A
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Figure 5: Changes in the proportions of the major effector T-helper cell subsets in RA patients in whom long-term follow-up data from the
initiation of anti-TNF therapy were available (n = 13). 7 patients from the initial short-term cohort (7) proved to be long-term responders,
whereas the other 6 patients lost the initial response and therefore belonged to the nonresponder group. Measurement time points:
baseline: at anti-TNF initiation, short term: 8 weeks of anti-TNF treatment (previously published data (7), long-term: current
measurement results after long-standing anti-TNF treatment. Data are presented as median (horizontal line within boxes), 25 and 75
percentile (horizontal borders of the boxes), and minimum and maximum (whiskers). Ap < 0 05 versus baseline, Bp < 0 05 versus
short term.
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between future anti-TNF responders and nonresponders
with a sensitivity of 71.4% and a specificity of 83.3%
(p = 0 054) (Figure 7).
4. Discussion
Our results present a comprehensive overview of the
alterations in the composition of the T-cell subset in RA
patients on long-term anti-TNF or IL-6R blocker therapy
with a focus on changes in the naive/memory subtypes, the
most important effector pathways (Th1, Th2, Th17, and
Treg), as well as various activation markers (CD25, CD69,
and HLA-DR). Key findings are that, during anti-TNF
therapy, the reduced percentages of Tregs found in active,
untreated disease gradually normalize, while the proportion
of naive T-cells decreases, and, surprisingly, the proportions
of Th1 and Th17 cells, which are important drivers of RA
activity, also remain increased and even further rise with
follow-up. Some of these alterations were dependent on the
therapeutic response, whereas many of them seemed to be a
characteristic effect of anti-TNF therapy independent of its
disease-controlling effect.
There are a few reports about T-cell subset changes
during anti-TNF therapy; most of them involve relatively
low numbers of patients [8, 9, 12, 13], use only short-term
follow-up [7, 8, 11, 12], and the majority are restricted to
the determination of Treg and Th17 proportions. Although
most of the studies describe an increase in Treg and a
decrease in Th17 frequencies [8, 11, 12, 14], opposing results
have also been published [7, 10, 15]. Chen et al. found that
Th17 cell counts decrease in anti-TNF-treated patients who
had shown a good response to therapy, whereas in nonre-
sponders, Th17 cell percentages increased [14]. In our
previous study involving only 8 weeks of short-term follow-
up, we have demonstrated that Th1 and Treg frequencies
increased compared with the values measured at the time of
the initiation of anti-TNF therapy, but the values remained
significantly different from those of healthy controls [7].
With extended follow-up, the difference has disappeared
relating to Tregs, whereas other alterations have remained
or new ones have developed. The ratio of naïve T-cells
decreased, that of Th1 or Th17 cells increased, CD4+CD69
cell counts decreased, and CD4+HLA-DR+ cells increased,
and some of these changes were different between responders
and nonresponders. The discrepancies among the published
results may be explained by differences in the follow-up time,
the surface markers used, or the patient populations. Based
on our previous and present data, we conclude that short-
term follow-up is not suitable to capture the T-cell subset
alterations occurring during anti-TNF or IL-6R therapy and
that changes within the T-cell composition probably progress
continuously despite the decrease in the inflammatory
activity during treatment.
The increase of Th17 on both types of therapies and of
Th1 on anti-TNF therapy, as well as of various activated
T-cell subtypes, may be explained by the fact that both
anti-TNF and anti-IL-6R therapies exert their action by
the inhibition of the terminal phase of the effector arm
of the autoimmune process (i.e., cytokine action), and
the differentiation and the activation of naive T-cells by
the permanent antigenic stimuli may be left unchanged.
The elevation of the proportion of T-cells bearing the late
activation marker HLA-DR, the decrease of CD4+CD25+
intermediate activation marker-positive cells, and the fact
that these changes were more evident among anti-TNF
responders than in nonresponders also support this
hypothesis. In this regard, it would be interesting to
examine the T-cell proportion changes during B-cell
depleting or costimulation inhibiting therapies, which
influence the afferent phase of the immune response. On
the other hand, we have found that Treg frequency grad-
ually normalizes during both TNF- and IL-6R-blocking
therapies. While patients with early, untreated active RA
display markedly low Treg proportions, both classes of
biological therapies seem to restore this abnormality. The
increase in Treg proportion starts soon after the initiation
of anti-TNF-therapy, but the changes become statistically
significant only after long-term treatment. Restoration of
tolerance, as shown by the normalization of Treg numbers,
seems to be a consistent phenomenon during the pro-
longed therapy of RA. As the frequencies of many other
T-cell subtypes remained different from healthy controls,
CD4 CD69 CD8 CD69
A
A
25
20
15
10
5
0
Switch 1x Switch 2x Switch 3x
25
20
15
10
5
0
Switch 1x Switch 2x Switch 3x
Figure 6: The frequencies of CD4+CD69+ and of CD8+CD69+ cells in anti-IL-6R responder RA patients grouped according to the number
of previous switches in anti-TNF therapy before the initiation of the present tocilizumab treatment. Numbers indicate percentages within the
CD4+ or CD8+ T-cells, as applicable. Ap < 0 05 versus 1x switch.
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irrespective of therapy-response, we presume that anti-
TNF or IL-6R blocker therapies do not exert their phar-
macological actions through the influence on the T-cell
subsets other than Tregs, but rather by reducing the levels
of acute phase reactants, or synovial cytokine or chemo-
kine production. A further factor that should be consid-
ered is that despite Th17 proportion remained increased,
the ratio of Th17/Treg tended to approach the ratio
observed in healthy controls. Analogously to our findings,
Teniente-Serra et al. have found that multiple sclerosis
patients treated with natalizumab (monoclonal antibody
to the integrin CD49d) had an increased percentage of
early effector and central memory T-cells, as well as of
early thymic emigrant T-cells, as compared with untreated
patients, indicating that T-cell activation may proceed
despite the inflammatory process is blocked by the inhibi-
tion of the effector steps [25].
The dynamics of the transformation of the T-cell pool
can be estimated from our studies: there are relatively great
differences between the T-cell phenotype at 8 weeks and 6
months of biological therapy, whereas only minor changes
(i.e., further increase in naïve T-cells) occur after 6 months.
It indicates that a few months of follow-up are insufficient
to address this question, but 6 months is suggested to be a
relevant measurement point for T-cell subtype analysis,
validating our definition of long-term treatment of at least
6 months.
RA patients on effective long-term tocilizumab ther-
apy in our study are characterized by normal Treg num-
bers, increased Th2 and Th17 cell proportion, and by
decreased frequencies of CD8 and naive (both CD4+ and
CD8+) cells. Th1 cell percentages were lower but those of
CD69+-activated CD4+ and CD8+ cells were higher than
anti-TNF-treated patients. This finding confirms our
hypothesis that different classes of targeted therapies have
different impacts on the T-cell homeostasis although their
efficacy and tolerability as assessed by clinical and routine lab-
oratory examinations are identical. The proportions of vari-
ous lymphocyte subsets during IL-6R blocker therapy were
followed by Kikuchi et al. [16]. Our results add further knowl-
edge to their results by including several T-cell subtypes not
analyzed before and the inclusion of a healthy control group.
Common findings in their examinations and ours are the
importance of the normalization of Treg counts, the decrease
in the frequencies of CD8+ cells and naive T-cells, and an
increase in those of CD69+-activated T-cells. Although they
did not find a significant change in Th1, Th2, or Th17 preva-
lences, their results also underline that a decrease in the
frequencies of these activated T-cell subsets is not a finding
that can be expected during tocilizumab treatment.
High body of data confirm that biological therapies can,
in general, be regarded as safe also when administered for
several years, but the label of each agent warns that their
administration in patients with previous malignancy needs
individual risk assessment and caution. It was also suggested
that long-term rituximab therapy, another type of biological
with specificity to B-cells targeting CD20, produces T-cell
alterations similar to immunosenescence characterized by
an increased susceptibility to infections [26] and that JC virus
reactivation causing progressive multifocal leukoencephalo-
pathy may be preceded by specific T-cell subset alterations
in natalizumab-treated multiple sclerosis patients [27].
Long-term cohort studies, and especially registry data,
should be paralleled with T-cell phenotype analyses to
discern whether a sustained decrease of CD8-positive (cyto-
toxic) T-cells and Th1 cells may impair the protection against
carcinogenesis or the reactivation or acquisition of some
types of infection.
The most important activation molecules expressed on
T lymphocytes can be classified as early activation markers,
such as CD69 and CD25, and late activation markers, such
as HLA-DR. CD69 is generally regarded as the earliest activa-
tion cell surface marker induced by a mitogenic stimulus.
The expression of CD69 molecule is not restricted to
activated lymphocytes, as activated neutrophils and eosino-
phils can also express CD69. Moreover, platelets, epidermal
Langerhans cells, and bone marrow myeloid precursors
express CD69 constitutively. The engagement of CD69 can
activate NK and T-cells, resulting in increased cytotoxic
activity and proinflammatory cytokine production [28].
CD25, or the alpha subunit of the IL-2 receptor, is involved
in the early stage of lymphocyte activation, but it also seems
to be critical in maintaining self-tolerance and immune
homeostasis. Early work on CD4+CD25 high+ cells later
termed as regulatory T-cells showed that their activation via
their T-cell receptor (TCR) generates suppressor cells that
are capable of nonspecifically suppressing the activation of
CD4+ or CD8+ T-cells [29]. HLA-DRmolecules are involved
in antigen processing and presentation, mediating antigen-
specific T-cell activation. They are not expressed by naïve
T-cells, but their expression is induced during T-cell activa-
tion, driven primarily by class-II transactivator, through the
activation of its promoter by CREB/ATF or AML/Runx
transcription factors [30]. During the follow-up analysis of
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Figure 7: Receiver-operator characteristic (ROC) curve of
CD4CD69 positivity. Predictive potential of the percentage of
CD4CD69-positive cells at baseline (start of anti-TNF) to long-term
response to therapy. CD4+CD69+ T-cell percentage< 2.43 has the
highest likelihood ratio (4.29 (CI: 0.58–1.06) to discriminate
between future anti-TNF responders and nonresponders
(sensitivity: 71.4%, specificity: 83.3%, p = 0 054).
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anti-TNF responder and nonresponder patients, the early
activation marker CD69 emerged as the most useful predic-
tive marker of medication response. If the proportion of
CD4+CD69+ cells is lower than 2.43 in an RA patient at
the start of anti-TNF therapy, the patient has a high likeli-
hood to show a good response to this biological treatment.
This correlation is further supported by our analysis of IL-
6R responder patients with previous anti-TNF switch,
because in those who had three times produced an incom-
plete response to anti-TNF therapy previously. The
prevalences of CD4CD69+ and CD8CD69+ markers are
significantly higher as compared to those who failed only
one anti-TNF inhibitor. These results confirm not only the
potential predictive role of the low expression of CD4CD69
marker for a good therapeutic response to anti-TNF therapy,
but also aid in the drug choice after an incomplete response
to a TNF-inhibitor. Since all anti-TNF nonresponders who
had previously switched three times and were characterized
by higher CD4CD69 and CD8CD69 expressions became
long-term anti-IL-6R responders, we propose that for
patients with high CD4CD69 expression, after an incomplete
TNF-inhibitor treatment, a switch to anti-IL-6R therapy is
the preferred choice, although it has to be noted that we do
not have information on the percentage of CD4CD69+ cells
at the initiation of IL-6R blocker in our patients, and conse-
quently its predictive power needs further confirmation.
Whereas several novel biochemical or clinical biomarkers
that aid in the differential diagnoses, disease subset definition
or the prediction of the progression of irreversible organ
damage has recently been identified [31–33]. There is sub-
stantial deficiency in the availability of predictors of the
response to immunosuppressive treatment in general, or to
particular therapeutic agents. Since almost all chronic
inflammatory rheumatic diseases are regarded as heteroge-
neous syndromes with substantial genetic variability among
patients with the same diagnoses, and this genetic heteroge-
neity renders most of the therapeutic agents effective only
in a subset of patients, analysis of susceptibility factors to
drug response and adverse effects is crucial. As the paradigm
of early, effective, and targeted interventions has become a
general requirement in order to prevent early tissue damage
and to modify the course of the disease in the long run
[34–36] and also for reasons of cost-effectiveness, and for
patient safety, biomarker-driven, personalized therapy
choice is favoured over random or uniformized treatment
decisions. The present results of the predictive value of
CD69 marker seem, therefore, to be worth being validated
in higher number of patients as a marker for the personalized
choice of the appropriate class of biological therapy for the
given RA patient.
A limitation of our study is the lack of the inclusion of an
IL-6 nonresponder patient group, which would have made
the study even more comprehensive.
In conclusion, Treg proportion is normalized in RA
patients treated with long-standing anti-TNF or IL-6R
blocker therapies. Our study examined a wide spectrum of
T-cell subtypes and indicated that the remaining compo-
nents of the T-cell pool are consistent with a permanent
antigen-driven immunological process. In contrast to our
former study with a short-term follow-up, we could observe
a more complex alteration in the T-cell phenotype and that
these changes are not much different among the particular
anti-TNF agents—although the relatively low number of
patients treated with each specific anti-TNF drug precludes
firm conclusions in this regard. However, IL-6R blockade
skews the adaptive immune system into a rather different
profile, while the restoration of Treg proportion is an impor-
tant common end-point during both therapies. CD4+CD69+
cell percentage is a potential candidate for the prediction of
treatment response to anti-TNF therapy.
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